Skip to main content

Table 2 Baseline characteristics of the study population (n = 2611) according to tertiles of HOMA-IR

From: Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. The SMART study

HOMA-IR, tertiles Tertile 1 Tertile 2 Tertile 3
HOMA-IR 1.1 ± 0.4 2.3 ± 0.4 4.9 ± 2.3
(Range) 0.4-1.7 1.7-3.0 3.0-23.3
  n = 872 n = 870 n = 869
Age (years) 59.4 ± 10.5 60.0 ± 10.4 59.4 ± 10.4
Male gender, n (%) 593 (68) 611 (70) 658 (76)
Body mass index (kg/m2) 24.7 ± 3.1 26.7 ± 3.4 28.9 ± 4.2
Abdominal adipose tissue (cm) 7.6 ± 2.0 8.7 ± 2.2 10.1 ± 2.5
Current smoking, n (%) 288 (33) 245 (28) 251 (29)
Creatinin clearance MDRD (ml/min/1.73 m2) 79.0 ± 16.8 75.4 ± 16.4 74.0 ± 18.3
Medication    
Lipid-lowering agents, n (%) 624 (72) 671 (77) 709 (82)
Anti-platelet agents, n (%) 689 (79) 723 (83) 724 (83)
Blood pressure-lowering agents, n (%) 588 (67) 654 (75) 751 (86)
Location of manifest arterial disease    
Cerebrovascular disease, n (%) 263 (30) 261 (30) 206 (24)
Coronary heart disease, n (%) 509 (58) 540 (62) 614 (71)
Peripheral arterial disease, n (%) 138 (16) 127 (15) 133 (16)
Abdominal aortic aneurysm, n (%) 56 (6) 64 (7) 44 (5)
Atherosclerotic burden    
CIMT(mm) 0.88 ± 0.24 0.89 ± 0.25 0.89 ± 0.22
Albumin/creatinin ratio > 3.0 mg/mmol, n (%) 120 (14) 120 (14) 135 (16)
Metabolic syndrome components    
Metabolic syndrome (ATPIII), n (%) 148 (17) 232 (37) 582 (67)
Waist circumference (cm) 87.6 ± 10.6 94.0 ± 10.5 100.5 ± 11.8
Blood pressure systolic (mmHg) 138 ± 20 141 ± 21 142 ± 21
Blood pressure diastolic (mmHg) 81 ± 11 83 ± 11 84 ± 11
Fasting glucose (mmol/l) 5.4 ± 0.5 5.7 ± 0.6 6.1 ± 0.8
Triglycerides (mmol/l) 1.0 (0.8-1.4) 1.2 (0.9-1.7) 1.1 (0.9-1.3)
HDL-cholesterol (mmol/l) 1.4 ± 0.4 1.3 ± 0.4 1.1 ± 0.3
LDL-cholesterol (mmol/l) 2.7 ± 0.9 2.7 ± 1.0 2.6 ± 0.9
hs-CRP (mg/l) 1.4 (0.6-3.2) 1.6 (0.8-3.7) 2.1 (1.0-4.3)
Fasting insulin (mIU/l) 4.8 ± 1.6 9.1 ± 1.5 17.9 ± 7.8
QUICKI 0.32 ± 0.05 0.26 ± 0.01 0.22 ± 0.02